146 related articles for article (PubMed ID: 33548634)
1. Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation.
Maciuszek M; Ortega-Gomez A; Maas SL; Perretti M; Merritt A; Soehnlein O; Chapman TM
Eur J Med Chem; 2021 Mar; 214():113194. PubMed ID: 33548634
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists.
Maciuszek M; Ortega-Gomez A; Maas SL; Garrido-Mesa J; Ferraro B; Perretti M; Merritt A; Nicolaes GAF; Soehnlein O; Chapman TM
Eur J Med Chem; 2021 Dec; 226():113805. PubMed ID: 34536667
[TBL] [Abstract][Full Text] [Related]
3. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
[TBL] [Abstract][Full Text] [Related]
5. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
Lind S; Sundqvist M; Holmdahl R; Dahlgren C; Forsman H; Olofsson P
Biochem Pharmacol; 2019 Aug; 166():163-173. PubMed ID: 31085160
[TBL] [Abstract][Full Text] [Related]
6. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.
Stama ML; Ślusarczyk J; Lacivita E; Kirpotina LN; Schepetkin IA; Chamera K; Riganti C; Perrone R; Quinn MT; Basta-Kaim A; Leopoldo M
Eur J Med Chem; 2017 Dec; 141():703-720. PubMed ID: 29102463
[TBL] [Abstract][Full Text] [Related]
7. Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.
Asahina Y; Wurtz NR; Arakawa K; Carson N; Fujii K; Fukuchi K; Garcia R; Hsu MY; Ishiyama J; Ito B; Kick E; Lupisella J; Matsushima S; Ohata K; Ostrowski J; Saito Y; Tsuda K; Villarreal F; Yamada H; Yamaoka T; Wexler R; Gordon D; Kohno Y
J Med Chem; 2020 Sep; 63(17):9003-9019. PubMed ID: 32407089
[TBL] [Abstract][Full Text] [Related]
8. Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling.
Zhang S; Gong H; Ge Y; Ye RD
Pharmacol Res; 2020 Nov; 161():105117. PubMed ID: 32768626
[TBL] [Abstract][Full Text] [Related]
9. The Lipidated Peptidomimetic Lau-((S)-Aoc)-(Lys-βNphe)6-NH2 Is a Novel Formyl Peptide Receptor 2 Agonist That Activates Both Human and Mouse Neutrophil NADPH Oxidase.
Holdfeldt A; Skovbakke SL; Winther M; Gabl M; Nielsen C; Perez-Gassol I; Larsen CJ; Wang JM; Karlsson A; Dahlgren C; Forsman H; Franzyk H
J Biol Chem; 2016 Sep; 291(38):19888-99. PubMed ID: 27422818
[TBL] [Abstract][Full Text] [Related]
10. Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.
Stepniewski TM; Filipek S
Bioorg Med Chem; 2015 Jul; 23(14):4072-81. PubMed ID: 25882522
[TBL] [Abstract][Full Text] [Related]
11. FPR2/ALXR agonists and the resolution of inflammation.
Corminboeuf O; Leroy X
J Med Chem; 2015 Jan; 58(2):537-59. PubMed ID: 25365541
[TBL] [Abstract][Full Text] [Related]
12. Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity.
Ge Y; Zhang S; Wang J; Xia F; Wan JB; Lu J; Ye RD
FASEB J; 2020 May; 34(5):6920-6933. PubMed ID: 32239559
[TBL] [Abstract][Full Text] [Related]
13. Lack of activity of 15-epi-lipoxin A₄ on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function.
Planagumà A; Domenech T; Jover I; Ramos I; Sentellas S; Malhotra R; Miralpeix M
Clin Exp Immunol; 2013 Aug; 173(2):298-309. PubMed ID: 23607720
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A
de Gaetano M; Tighe C; Gahan K; Zanetti A; Chen J; Newson J; Cacace A; Marai M; Gaffney A; Brennan E; Kantharidis P; Cooper ME; Leroy X; Perretti M; Gilroy D; Godson C; Guiry PJ
J Med Chem; 2021 Jul; 64(13):9193-9216. PubMed ID: 34138563
[TBL] [Abstract][Full Text] [Related]
15. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
16. Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways.
Bozinovski S; Anthony D; Anderson GP; Irving LB; Levy BD; Vlahos R
Pharmacol Ther; 2013 Dec; 140(3):280-9. PubMed ID: 23880288
[TBL] [Abstract][Full Text] [Related]
17. The proteolytically stable peptidomimetic Pam-(Lys-βNSpe)6-NH2 selectively inhibits human neutrophil activation via formyl peptide receptor 2.
Skovbakke SL; Heegaard PM; Larsen CJ; Franzyk H; Forsman H; Dahlgren C
Biochem Pharmacol; 2015 Jan; 93(2):182-95. PubMed ID: 25462815
[TBL] [Abstract][Full Text] [Related]
18. Insights into the Activation Mechanism of the ALX/FPR2 Receptor.
Schmitz Nunes V; Rogério AP; Abrahão O
J Phys Chem Lett; 2020 Nov; 11(21):8952-8957. PubMed ID: 33030905
[TBL] [Abstract][Full Text] [Related]
19. What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4?
Forsman H; Önnheim K; Andreasson E; Dahlgren C
Scand J Immunol; 2011 Sep; 74(3):227-234. PubMed ID: 21535079
[TBL] [Abstract][Full Text] [Related]
20. FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils.
Gabl M; Holdfeldt A; Sundqvist M; Lomei J; Dahlgren C; Forsman H
Biochem Pharmacol; 2017 Dec; 145():114-122. PubMed ID: 28855087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
